Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics Inc.

In a report released on July 17, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Tango Therapeutics, with a price target of $40....

Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)

There’s no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TNGX	$26.65	-0.26%	1.95M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TNGX	$26.65	-0.3%	1.95M
3
4
5
6

TNGX

TNGX

Get Tango Therapeutics Inc. Data in Excel

Get Tango Therapeutics Inc. Data in Excel